1
|
Kranzfelder M, Büchler P and Friess H:
Surgery within multimodal therapy concepts for esophageal squamous
cell carcinoma (ESCC): The MRI approach and review of the
literature. Adv Med Sci. 54:158–169. 2009. View Article : Google Scholar : PubMed/NCBI
|
2
|
Chen ZL, Zhao XH, Wang JW, Li BZ, Wang Z,
Sun J, Tan FW, Ding DP, Xu XH, Zhou F, et al: microRNA-92a promotes
lymph node metastasis of human esophageal squamous cell carcinoma
via E-cadherin. J Biol Chem. 286:10725–10734. 2011. View Article : Google Scholar : PubMed/NCBI
|
3
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Ma S, Bao JYJ, Kwan PS, Chan YP, Tong CM,
Fu L, Zhang N, Tong AHY, Qin YR, Tsao SW, et al: Identification of
PTK6, via RNA sequencing analysis, as a suppressor of esophageal
squamous cell carcinoma. Gastroenterology. 143:675–686.e12. 2012.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Chen W, He Y, Zheng R, Zhang S, Zeng H,
Zou X and He J: Esophageal cancer incidence and mortality in China,
2009. J Thorac Dis. 5:19–26. 2013.PubMed/NCBI
|
6
|
Lagergren J and Lagergren P: Oesophageal
cancer. BMJ. 341:c62802010. View Article : Google Scholar : PubMed/NCBI
|
7
|
Sant M, Allemani C, Santaquilani M, Knijn
A, Marchesi F and Capocaccia R; EUROCARE Working Group, :
EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999.
Results and commentary. Eur J Cancer. 45:931–991. 2009. View Article : Google Scholar : PubMed/NCBI
|
8
|
Liu AM, Xu Z and Luk JM: An update on
targeting Hippo-YAP signaling in liver cancer. Expert Opin Ther
Targets. 16:243–247. 2012. View Article : Google Scholar : PubMed/NCBI
|
9
|
Hong L, Cai Y, Jiang M, Zhou D and Chen L:
The Hippo signaling pathway in liver regeneration and
tumorigenesis. Acta Biochim Biophys Sin (Shanghai). 47:46–52. 2015.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Overholtzer M, Zhang J, Smolen GA, Muir B,
Li W, Sgroi DC, Deng CX, Brugge JS and Haber DA: Transforming
properties of YAP, a candidate oncogene on the chromosome 11q22
amplicon. Proc Natl Acad Sci USA. 103:pp. 12405–12410. 2006;
View Article : Google Scholar : PubMed/NCBI
|
11
|
Wang X, Su L and Ou Q: Yes-associated
protein promotes tumor development in luminal epithelial derived
breast cancer. Eur J Cancer. 48:1227–1234. 2012. View Article : Google Scholar : PubMed/NCBI
|
12
|
Ge L, Smail M, Meng W, Shyr Y, Ye F, Fa
KH, Li X, Zhou HM and Bhowmick NA: Yes-associated protein
expression in head and neck squamous cell carcinoma nodal
metastasis. PLoS One. 6:e275292011. View Article : Google Scholar : PubMed/NCBI
|
13
|
Cui ZL, Han FF, Peng XH, Chen X, Luan CY,
Han RC, Xu WG and Guo XJ: Yes-associated protein 1 promotes
adenocarcinoma growth and metastasis through activation of the
receptor tyrosine kinase Axl. Int J Immunopathol Pharmacol.
25:989–1001. 2012. View Article : Google Scholar : PubMed/NCBI
|
14
|
Avruch J, Zhou D and Bardeesy N: YAP
oncogene overexpression supercharges colon cancer proliferation.
Cell Cycle. 11:1090–1096. 2012. View Article : Google Scholar : PubMed/NCBI
|
15
|
Wang J, Ma L, Weng W, Qiao Y, Zhang Y, He
J, Wang H, Xiao W, Li L, Chu Q, et al: Mutual interaction between
YAP and CREB promotes tumorigenesis in liver cancer. Hepatology.
58:1011–1020. 2013. View Article : Google Scholar : PubMed/NCBI
|
16
|
Muramatsu T, Imoto I, Matsui T, Kozaki K,
Haruki S, Sudol M, Shimada Y, Tsuda H, Kawano T and Inazawa J: YAP
is a candidate oncogene for esophageal squamous cell carcinoma.
Carcinogenesis. 32:389–398. 2011. View Article : Google Scholar : PubMed/NCBI
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Liu AM, Wong KF, Jiang X, Qiao Y and Luk
JM: Regulators of mammalian Hippo pathway in cancer. Biochim
Biophys Acta. 1826:357–364. 2012.PubMed/NCBI
|
19
|
Zender L, Spector MS, Xue W, Flemming P,
Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, et
al: Identification and validation of oncogenes in liver cancer
using an integrative oncogenomic approach. Cell. 125:1253–1267.
2006. View Article : Google Scholar : PubMed/NCBI
|
20
|
Steinhardt AA, Gayyed MF, Klein AP, Dong
J, Maitra A, Pan D, Montgomery EA and Anders RA: Expression of
Yes-associated protein in common solid tumors. Hum Pathol.
39:1582–1589. 2008. View Article : Google Scholar : PubMed/NCBI
|
21
|
Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT,
Zender L, Lowe SW, Poon RT and Luk JM: Yes-associated protein is an
independent prognostic marker in hepatocellular carcinoma. Cancer.
115:4576–4585. 2009. View Article : Google Scholar : PubMed/NCBI
|
22
|
Wang Y, Dong Q, Zhang Q, Li Z, Wang E and
Qiu X: Overexpression of yes-associated protein contributes to
progression and poor prognosis of non-small-cell lung cancer.
Cancer Sci. 101:1279–1285. 2010. View Article : Google Scholar : PubMed/NCBI
|
23
|
Dubreuil G, Magliano M, Dubrana MP, Lozano
J, Lecomte P, Favery B, Abad P and Rosso MN: Tobacco rattle virus
mediates gene silencing in a plant parasitic root-knot nematode. J
Exp Bot. 60:4041–4050. 2009. View Article : Google Scholar : PubMed/NCBI
|
24
|
Li JC, Yang XR, Sun HX, Xu Y, Zhou J, Qiu
SJ, Ke AW, Cui YH, Wang ZJ, Wang WM, et al: Up-regulation of
Krüppel-like factor 8 promotes tumor invasion and indicates poor
prognosis for hepatocellular carcinoma. Gastroenterology.
139:2146–2157. 2010. View Article : Google Scholar : PubMed/NCBI
|
25
|
Tsujimoto Y and Shimizu S: Bcl-2 family:
Life-or-death switch. FEBS Lett. 466:6–10. 2000. View Article : Google Scholar : PubMed/NCBI
|
26
|
Dhillon AS, Hagan S, Rath O and Kolch W:
MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290.
2007. View Article : Google Scholar : PubMed/NCBI
|
27
|
Surget S, Khoury MP and Bourdon JC:
Uncovering the role of p53 splice variants in human malignancy: A
clinical perspective. Onco Targets Ther. 7:57–68. 2013.PubMed/NCBI
|